Momenta Pharmaceuticals, Inc.

Janssen Biotech, Inc.

James Meador, Iii

Carlos J Bosques

Leona E Ling

Nathaniel J Washburn

Dorota A Bulik

James S Huston

Jonathan C Lansing

Daniel Ortiz

Laura Rutitzky

Naveen Bhatnagar

David J King

Marilyn Kehry

Brian Edward Collins

Sucharita Roy

Anthony Manning

Sean Smith

Julia Brown

Lynn Markowitz

Sathya Prabbhakar

Maurice Gaston Hains

James R Myette

Birgit Corinna Schultes

Jay Duffner

Jan Hillson

Elma Kurtagic

Christopher Beneduce

Brigit C Schultes

Brian E Collins

The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 (α11β1), as well as methods of making and using such antibodies.

Antibodies against integrin alpha 11 beta 1

The present invention relates to methods of using biologically active Fc domain-containing therapeutic constructs (Fc constructs) to induce immune cell activation of the immune response in a subject, and for example, to treat diseases such as cancers and infections in a subject. Such Fc constructs may include 5 or more Fc domains.

Methods related to engineered Fc constructs

The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.

Compositions and methods related to engineered Fc constructs

The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.

FcRn antibodies and methods of use thereof

The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.

Modified glycoproteins

Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.

Methods and compositions related to high mannose glycans are described.

High mannose glycans

A glycosyl transferase from Chinese hamster and related methods are described.

Glycosyl transferase from Chinese hamster and related methods

Growing community of inventors

Framingham, MA, United States of America

James Meador, Iii